SECOND AMENDMENT TO THE LICENSE AGREEMENT OF FEBRUARY 1, 2005 BETWEEN COLUMBIA AND OMNIMMUNE CORP. June 10, 2005 Harris A. Lichtenstein, Ph.D. President and CEO Omnimmune Corp.
Exhibit
10.10
COLUMBIA
UNIVERSITY SCIENCE AND TECHNOLOGY VENTURES
SECOND
AMENDMENT TO THE LICENSE AGREEMENT OF
FEBRUARY
1, ▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ AND OMNIMMUNE CORP.
June 10,
2005
▇▇▇▇▇▇ ▇.
▇▇▇▇▇▇▇▇▇▇▇▇, Ph.D.
President
and CEO
Omnimmune
Corp.
▇▇▇▇ ▇▇▇▇
▇▇▇ ▇▇▇▇▇
▇▇▇▇▇
▇▇▇
▇▇▇▇▇▇▇,
▇▇▇▇▇ ▇▇▇▇▇
Dear
▇▇▇▇▇▇:
The
Agreement between Omnimmune Corp. and The Trustees of Columbia University in the
City of New York, dated February 1, 2005 (“Agreement”),
as amended by the amendment of March 29, 2005 is hereby further amended
effective May 31, 2005, as follows:
|
1.
|
Section
17 (a) is amended to read as
follows:
|
|
a.
|
This Agreement shall
be effective as of the date first recited above and shall continue in full
force and effect until its expiration or termination
in accordance with this Section 17; provided however that
if the Stock Purchase Agreement or the Stockholders Agreement involving
Columbia and Omnimmune is not fully executed within 180 days of the
effective date of this Agreement, then this Agreement is null
and
void.
|
All other
terms and conditions of the Agreement shall remain in full force and
effect, except as expressly amended herein.
Please
indicate your agreement to the Letter Amendment by signing where indicated
below, and returning one original signed Letter to my attention.
Very
truly yours,
/s/
▇▇▇▇ ▇.
▇▇▇▇▇▇▇▇
▇▇▇▇ ▇.
▇▇▇▇▇▇▇▇
Senior
Director
Science
and Technology Ventures
The
Trustees of Columbia University in the City of New York
AGREED
AND ACKNOWLEDGED:
OMNIMMUNE
CORP.
By:/s/
▇▇▇▇▇▇ ▇.
▇▇▇▇▇▇▇▇▇▇▇▇
President
Date:
7/02/05